Key result
In patients with tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation, DOAC use was associated with a nearly six-fold increase in major bleeding events compared to warfarin.
Why the study?
Adults with congenital heart disease, particularly ToF and PA-IVS, have an increased risk of AF and complications, but their thromboembolic and bleeding risks and risk score utility require evaluation.
Does DOAC use compared to warfarin affect bleeding risk in patients with Tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation?
Cohort (n=300)
Yes
Does DOAC use compared to warfarin affect bleeding risk in patients with Tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation?
In patients with Tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation, DOACs are associated with a significantly higher bleeding risk compared to warfarin, suggesting warfarin may be the safer anticoagulant in this population.
Answers are grounded in this paper and cite their sources.
CHA2DS2-VASc and HAS-BLED may stratify TE and bleeding risk in ToF/PA-IVS with AF; leaves open dedicated validation before clinical use.
Introduction Adults with congenital heart disease (CHD), particularly tetralogy of Fallot (ToF) and pulmonary atresia with intact ventricular septum (PA-IVS), are at increased risk for atrial fibrillation (AF) and its complications. We evaluated thromboembolic and bleeding risks in this population and assessed the predictive value of CHA 2 DS 2 -VASc and HAS-BLED scores. Methods In this retrospective cohort study, patients with ToF-PS, ToF-PA, or PA-IVS and AF were identified across Mayo Clinic sites (1999–2023) were analyzed. Primary outcomes were thromboembolism (stroke, TIA, systemic embolism) and major bleeding. Cox regression controlled for age; anticoagulation exposure was treated as time-varying. Risk score performance was evaluated using ROC curves. Results 300 patients with ToF-PS, ToF-PA, or PA-IVS were identified. Over 2,296 person-years, 12 thromboembolic events occurred (5.23/1000 person-years). Prior stroke, TIA, peripheral embolism, and Potts shunt were significant predictors. CHA 2 DS 2 -VASc had good discrimination (c-statistic 0.78); no events occurred in patients with a score of 0. Major bleeding occurred 69 times over 1,845 person-years (3.74/100 person-years), more frequently in ToF-PA (HR 2.05, p = 0.005), chronic AF, and those with Waterson shunts (HR 4.64, p = 0.013). DOAC use was associated with significantly higher bleeding risk than warfarin (HR 5.89, p < 0.001). The HAS-BLED score had limited predictive value (c-statistic 0.59) (figure 1). Discussion In CHD patients with AF, thromboembolic risk was low with anticoagulation, and CHA 2 DS 2 -VASc performed well. However, bleeding risk, particularly with DOACs and in patients with specific anatomical features, was high. Warfarin may be the safer anticoagulant in this population.
No takes yet. Share an insight, caveat, or question.
O’Shea et al. (2025) conducted a cohort in Tetralogy of Fallot and Pulmonary Atresia with Intact Ventricular Septum with Atrial Fibrillation (n=300). Direct Oral Anticoagulants (DOACs) vs. Warfarin was evaluated on Major bleeding events (HR 5.89, 95% CI 2.81-12.35, p=<0.001). In patients with tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation, DOAC use was associated with a nearly six-fold increase in major bleeding events compared to warfarin.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: